Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
1999-1-25
|
pubmed:abstractText |
Recent evidence indicates that B cell receptor signaling plays a role in the generation of the B-1 cell lineage that expresses the CD5 marker, and the CD95-mediated death plays an essential role in maintaining B cell tolerance. We therefore probed CD5 and CD95 expression on B cells from systemic lupus erythematosos (SLE) patients and control subjects. Firstly, in agreement with previous studies, we found that CD5 expression (11%) was relatively constant among control individuals. We also noted that the activation of B cells up-regulates this marker. Unexpectedly, we found that the B-1 cell subset is under-represented (3.9+/-0.3%) in SLE patients in an inactive stage of the disease. Together with related studies, these findings suggest that there is a correlation between CD5 expression and disease activity. Secondly, we found that CD95(+) B cells can be divided into two subsets expressing a high- (CD95(high)) and a low-density (CD95(low)) of CD95. There was no difference in the proportion of total CD95(+) B cells (23.5+/-2.8) in the two groups, but SLE patients in an inactive phase of the disease characteristically expressed a relatively high proportion (50%) of CD95(high) B cells. This finding would mean that a large fraction of B lymphocytes are sensitive to apoptosis, implying that autoantibody-producing B cells are derived from CD95(low) B cells and are relatively resistant to apoptosis.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0896-8411
|
pubmed:author | |
pubmed:copyrightInfo |
Copyright 1998 Academic Press.
|
pubmed:issnType |
Print
|
pubmed:volume |
11
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
449-55
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:9802928-Adult,
pubmed-meshheading:9802928-Aged,
pubmed-meshheading:9802928-Antigens, CD5,
pubmed-meshheading:9802928-Antigens, CD95,
pubmed-meshheading:9802928-Apoptosis,
pubmed-meshheading:9802928-Autoantibodies,
pubmed-meshheading:9802928-B-Lymphocyte Subsets,
pubmed-meshheading:9802928-B-Lymphocytes,
pubmed-meshheading:9802928-Case-Control Studies,
pubmed-meshheading:9802928-Female,
pubmed-meshheading:9802928-Gene Expression,
pubmed-meshheading:9802928-Humans,
pubmed-meshheading:9802928-Lupus Erythematosus, Systemic,
pubmed-meshheading:9802928-Lymphocyte Activation,
pubmed-meshheading:9802928-Male,
pubmed-meshheading:9802928-Middle Aged
|
pubmed:year |
1998
|
pubmed:articleTitle |
High-density expression of CD95 on B cells and underrepresentation of the B-1 cell subset in human lupus.
|
pubmed:affiliation |
Département d'Immunologie, Institut Pasteur, 28, rue du Dr Roux, Paris, 75015, France.
|
pubmed:publicationType |
Journal Article,
In Vitro,
Research Support, Non-U.S. Gov't
|